Indiana life sciences sector copes with shrinking VC pool
Venture funds nationwide crested at $100 billion in 2000, but that number last year had drooped to $18 billion.
Venture funds nationwide crested at $100 billion in 2000, but that number last year had drooped to $18 billion.
The 15-year-old company now has raised nearly $100 million in debt and equity financing and backing from individuals.
The three venture funds, which will focus on drug development, may be worth a total of $750 million, up to $250 million each, and Lilly will contribute as much as 20 percent of the money.
Heron Capital Equity Partners seeks to invest $1 million to $10 million in private companies headquartered within 250 miles of Indianapolis. HCEP is part of Heron Capital, one of the largest venture capital funds in the city.
Venture dollars for Hoosier companies are still few, but the flow of deals is picking up.
Venture dollars for Indiana life sciences companies are still few, but the flow of deals is picking up. Nine Hoosier companies
scored investments totaling $10.4 million during the first six months of the year.
Having invested in 10 companies since 2005 and with its $6 million pot of money running low, the Indiana Seed Fund is nearing
a crossroads.
Several Indiana companies are in a position, or soon will be, to launch an initial public offering. But don’t expect a wave
of new Indiana public companies. In the recession, with both revenue and profits down, companies may choose to wait until
they have better numbers to report.
Most local venture funds are standing pat because the economy is weak and they’re no longer
in fund-raising mode. Having invested most of their funds, the firms have shifted to the nurturing, or “harvesting”
stage, to try to improve investment returns.
The region’s blossoming technology sector is about to get another shot of financial fertilizer. The newly formed Allos
Ventures has raised $20 million from investors and plans to focus on early-stage tech companies.
Data-storage upstart Scale Computing on Monday announced a $9 million investment from Silicon Valley venture firm Benchmark
Capital. The infusion will help kick-start a global sales expansion focused on Japan and Europe, said Scale CEO Jeff
Ready.
Indiana entrepreneurs weary of hitting dry holes with angel investors and venture capitalists are turning to Chinese investors
who are eager to diversify their portfolios, latch onto American innovations—and take advantage of a federal visa program.
A Lebanon-based startup wants to build a call center here and add up to 300 jobs, but state and local officials are struggling
with a big obstacle to keeping the company here.
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009.
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009. That trend hit Indianapolis,
but the rest of the state actually saw an increase.
Jim Pearson knows a thing or two about raising money from venture capitalists. And he has some advice for BioCrossroads:
Teach entrepreneurs the value of money.
More than half of the venture capital fund’s original investors took a pass on its $58 million successor, the newly launched
INext.
The new INext fund is the successor to the $73 million Indiana Future Fund, which the life science initiative raised in 2003.
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly’s drug pipeline.